Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Actas Urol Esp (Engl Ed)
1 Adv Mater
1 Am J Surg Pathol
1 Anticancer Drugs
1 ANZ J Surg
5 Arch Esp Urol
2 Bioengineered
4 BJU Int
1 BMJ Case Rep
2 BMJ Open
1 Br J Cancer
1 Can J Urol
1 Cancer Commun (Lond)
1 Cancer Cytopathol
1 Cancer Gene Ther
1 Cancer Med
1 Cell Death Dis
1 CPT Pharmacometrics Syst Pharmacol
1 Curr Cancer Drug Targets
2 Curr Oncol Rep
1 Eur J Cancer
14 Eur Urol
1 Eur Urol Focus
1 Exp Clin Transplant
1 Front Cell Dev Biol
1 Front Genet
1 Hum Vaccin Immunother
1 Indian J Pathol Microbiol
1 Investig Clin Urol
1 Iran J Basic Med Sci
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Clin Pathol
2 J Endourol
1 J Histochem Cytochem
1 J Immunol Res
1 JAMA Netw Open
1 Mol Carcinog
1 Mol Cell Biochem
1 Nat Commun
3 Nihon Hinyokika Gakkai Zasshi
2 Open Vet J
1 Optom Vis Sci
1 Pathol Res Pract
1 PeerJ
1 PLoS One
1 Prog Urol
1 RSC Adv
1 Semin Ophthalmol
2 Support Care Cancer
1 Ther Adv Urol
20 Urol Oncol
1 World J Urol
1 Zhonghua Zhong Liu Za Zhi

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Actas Urol Esp (Engl Ed)

  1. CALDERON CORTEZ JF, Territo A, Fontana M, Gaya JM, et al
    Primary urethral carcinoma: Results from a single center experience.
    Actas Urol Esp (Engl Ed). 2022;46:70-77.
    PubMed         Abstract available

    Adv Mater

  2. CONG Z, Tang S, Xie L, Yang M, et al
    Magnetic-Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer.
    Adv Mater. 2022 Apr 22:e2201042. doi: 10.1002/adma.202201042.
    PubMed         Abstract available

    Am J Surg Pathol

  3. IAKYMENKO OA, Briski LM, Delma KS, Jorda M, et al
    Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34betaE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Am J Surg Pathol. 2022;46:454-463.
    PubMed         Abstract available

    Anticancer Drugs

  4. FUKATA S, Mizutani K, Yamamoto S, Kuno T, et al
    Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma.
    Anticancer Drugs. 2022;33:459-466.
    PubMed         Abstract available

    ANZ J Surg

    An ileal conduit retroperitoneal-pexy: An novel operative technique to treat the rare colonic internal hernia.
    ANZ J Surg. 2022;92:586-587.

    Arch Esp Urol

  6. WANG F, Yang J
    Correlations between forkhead box D1 expression and clinicopathological characteristics of patients with bladder cancer and influence on biological behaviors of bladder cancer cells.
    Arch Esp Urol. 2022;75:274-281.
    PubMed         Abstract available

  7. ELIZALDE BENITO FX, Sieso Gracia MR, Dolezal P, Martin Anoro LF, et al
    Abdominal mass as the first manifestation of bladder tumor.
    Arch Esp Urol. 2022;75:306-307.

    [Altered urinary pH as an aetiology of granulomas in urostomised patients.]
    Arch Esp Urol. 2022;75:296-299.
    PubMed         Abstract available

  9. SALAS E, Enguita L, Espilez R, Santander C, et al
    [Lymphoepithelioma-like bladder tumor. A rare variant.]
    Arch Esp Urol. 2022;75:300-305.
    PubMed         Abstract available

  10. LEI Y, Jiao D, Yao Z, Wang L, et al
    Prognostic values of preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and lymphocyte- to-monocyte ratio for patients with muscle- invasive bladder cancer undergoing radical cystectomy.
    Arch Esp Urol. 2022;75:287-294.
    PubMed         Abstract available


  11. XIA Y, Ge M, Xia L, Shan G, et al
    CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-kappaB activity.
    Bioengineered. 2022;13:10180-10190.
    PubMed         Abstract available

  12. CHENG J, Yang Q, Han X, Wang H, et al
    Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway.
    Bioengineered. 2022;13:10244-10257.
    PubMed         Abstract available

    BJU Int

  13. LEBRET T, Pignot G, Colombel M, Guy L, et al
    Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test.
    BJU Int. 2022;129:356-363.
    PubMed         Abstract available

  14. LEUNBACH TL, Stilling C, Tabor MB, Bjerggaard Jensen J, et al
    Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder.
    BJU Int. 2022;129:457-459.

  15. SUBIELA JD, Rodriguez Faba O, Aumatell J, Calderon J, et al
    Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
    BJU Int. 2022;129:542-550.
    PubMed         Abstract available

  16. HASHEM A, Abdellutif MM, Laymon M, Abdullateef M, et al
    Clinical efficacy of mebeverine for persistent nocturnal enuresis after orthotopic W-neobladder.
    BJU Int. 2022;129:387-393.
    PubMed         Abstract available

    BMJ Case Rep

  17. SINGH YP, Roy D, Jois B, Shetti M, et al
    Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.
    BMJ Case Rep. 2022;15.
    PubMed         Abstract available

    BMJ Open

  18. BIERI U, Scharl M, Sigg S, Szczerba BM, et al
    Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol.
    BMJ Open. 2022;12:e061421.
    PubMed         Abstract available

  19. AL-ZUBAIDI M, Viswambaram P, McCombie S, Liow E, et al
    (89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma.
    BMJ Open. 2022;12:e060478.
    PubMed         Abstract available

    Br J Cancer

  20. DE JONG JJ, Valderrama BP, Perera J, Juanpere N, et al
    Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01799.
    PubMed         Abstract available

    Can J Urol

  21. TEPLITSKY SL, Hensley PJ, Bettis A, James A, et al
    Operative duration and short term morbidity and mortality following radical cystectomy with urinary diversion.
    Can J Urol. 2022;29:11087-11094.
    PubMed         Abstract available

    Cancer Commun (Lond)

  22. HUANG M, Dong W, Xie R, Wu J, et al
    HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
    Cancer Commun (Lond). 2022 Apr 18. doi: 10.1002/cac2.12284.
    PubMed         Abstract available

    Cancer Cytopathol

  23. NOJIMA S, Terayama K, Shimoura S, Hijiki S, et al
    A deep learning system to diagnose the malignant potential of urothelial carcinoma cells in cytology specimens.
    Cancer Cytopathol. 2021;129:984-995.
    PubMed         Abstract available

    Cancer Gene Ther

  24. ZHANG Y, Liu Z, Wang X, Jian H, et al
    SHMT2 promotes cell viability and inhibits ROS-dependent, mitochondrial-mediated apoptosis via the intrinsic signaling pathway in bladder cancer cells.
    Cancer Gene Ther. 2022 Apr 14. pii: 10.1038/s41417-022-00470.
    PubMed         Abstract available

    Cancer Med

  25. LIU T, Li T, Zheng Y, Xu X, et al
    Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer.
    Cancer Med. 2022 Apr 20. doi: 10.1002/cam4.4745.
    PubMed         Abstract available

    Cell Death Dis

  26. HWANG TI, Chen PC, Tsai TF, Lin JF, et al
    Hsa-miR-30a-3p overcomes the acquired protective autophagy of bladder cancer in chemotherapy and suppresses tumor growth and muscle invasion.
    Cell Death Dis. 2022;13:390.
    PubMed         Abstract available

    CPT Pharmacometrics Syst Pharmacol

  27. MASTERS JC, Khandelwal A, di Pietro A, Dai H, et al
    Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
    CPT Pharmacometrics Syst Pharmacol. 2022;11:458-468.
    PubMed         Abstract available

    Curr Cancer Drug Targets

  28. ZHAO Y, Che J, Tian A, Zhang G, et al
    PBX1 Participates in Estrogen-Mediated Bladder Cancer Progression and Chemo-Resistance Affecting Estrogen Receptors.
    Curr Cancer Drug Targets. 2022 Apr 13. pii: CCDT-EPUB-122508.
    PubMed         Abstract available

    Curr Oncol Rep

  29. SHVERO A, Hubosky SG
    Management of Upper Tract Urothelial Carcinoma.
    Curr Oncol Rep. 2022;24:611-619.
    PubMed         Abstract available

  30. KUMAR D, Adeniran AJ
    Clinicopathological Review of Micropapillary Urothelial Carcinoma.
    Curr Oncol Rep. 2022;24:603-610.
    PubMed         Abstract available

    Eur J Cancer

  31. SONPAVDE GP, Sternberg CN, Loriot Y, Marabelle A, et al
    Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Eur J Cancer. 2022;163:55-65.
    PubMed         Abstract available

    Eur Urol

  32. HENSLEY PJ, Kamat AM
    Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:316-317.

  33. SJODAHL G, Abrahamsson J, Holmsten K, Bernardo C, et al
    Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Eur Urol. 2022;81:523-532.
    PubMed         Abstract available

  34. SAAD S, Osman NI, Chapple CR
    Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
    Eur Urol. 2022;81:e16-e17.

  35. CATHOMAS R, Lorch A, Bruins HM, Comperat EM, et al
    The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:95-103.
    PubMed         Abstract available

  36. CARMEN MIR M, Greenwell T, O'Kelly F, Proietti S, et al
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e26-e27.

  37. DEV S
    Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80
    Eur Urol. 2022;81:e25.

  38. RUTKA JT, Fleshner N, Nathens AB
    Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Euro Urol 2021;80:442-9.
    Eur Urol. 2022;81:e51.

  39. CLEMENTS MB, Atkinson TM, Dalbagni GM, Li Y, et al
    Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.
    Eur Urol. 2022;81:294-304.
    PubMed         Abstract available

  40. SHIGETA K, Matsumoto K, Oya M
    Reply to Fredrik Liedberg, Johan Abrahamsson, and Johannes Bobjer's Letter to the Editor re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy have Therapeutic Benefit for Node-positive Upper Tract Urothelial
    Eur Urol. 2022;81:e20-e21.

  41. MCGREGOR B, O'Donnell PH, Balar A, Petrylak D, et al
    Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
    Eur Urol. 2022;81:515-522.
    PubMed         Abstract available

  42. GALLIOLI A, Breda A, Palou J
    Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.
    Eur Urol. 2022;81:428-429.

  43. GEAVLETE P, Multescu R, Geavlete B
    Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19?
    Eur Urol. 2022;81:543.

  44. LIEDBERG F, Abrahamsson J, Bobjer J
    Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/
    Eur Urol. 2022;81:e18-e19.

  45. NAKAUMA-GONZALEZ JA, Rijnders M, van Riet J, van der Heijden MS, et al
    Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Eur Urol. 2022;81:331-336.
    PubMed         Abstract available

    Eur Urol Focus

  46. GRUNEWALD CM, Niegisch G, Albers P
    Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011.
    Eur Urol Focus. 2022 Apr 18. pii: S2405-4569(22)00078.
    PubMed         Abstract available

    Exp Clin Transplant

  47. KEENAN RA, Haroon U, Ryan P, Harrington B, et al
    Management of Urological Malignancy in Heart and Lung Transplant Recipients: An Irish National Cohort Study.
    Exp Clin Transplant. 2021;19:1069-1075.
    PubMed         Abstract available

    Front Cell Dev Biol

  48. GU H, Liang C
    Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients.
    Front Cell Dev Biol. 2022;10:725024.
    PubMed         Abstract available

    Front Genet

  49. LIU Q, Wang Y, Gao H, Sun F, et al
    An Individualized Prognostic Signature for Clinically Predicting the Survival of Patients With Bladder Cancer.
    Front Genet. 2022;13:837301.
    PubMed         Abstract available

    Hum Vaccin Immunother

  50. HE L, Wang X, Li C, Wan Y, et al
    Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer.
    Hum Vaccin Immunother. 2022;18:2035552.
    PubMed         Abstract available

    Indian J Pathol Microbiol

  51. YAMUC E, Barisik NO, Sensu S, Tarhan F, et al
    Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas.
    Indian J Pathol Microbiol. 2022;65:355-361.
    PubMed         Abstract available

    Investig Clin Urol

  52. TAE BS, Oh JJ, Jeong BC, Ku JH, et al
    Catheter-associated urinary tract infections in patients who have undergone radical cystectomy for bladder cancer: A prospective randomized clinical study of two silicone catheters (clinical benefit of antibiotic silicone material).
    Investig Clin Urol. 2022 Mar 28. pii: 63.e32. doi: 10.4111/icu.20210436.
    PubMed         Abstract available

    Iran J Basic Med Sci

  53. RAZZAGHDOUST A, Muhammadnejad S, Parvin M, Mofid B, et al
    Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.
    Iran J Basic Med Sci. 2021;24:1650-1655.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  54. CARRIL-AJURIA L, Martin-Soberon MC, de Velasco G, Agarwal N, et al
    Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review.
    J Cancer Res Clin Oncol. 2022;148:1097-1105.
    PubMed         Abstract available

    J Clin Oncol

  55. SONPAVDE GP, Mouw KW, Mossanen M
    Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
    J Clin Oncol. 2022;40:1275-1280.
    PubMed         Abstract available

    J Clin Pathol

  56. COLLA RUVOLO C, Wurnschimmel C, Wenzel M, Nocera L, et al
    Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder.
    J Clin Pathol. 2022;75:333-337.
    PubMed         Abstract available

    J Endourol

  57. BUBE SH, Kingo PS, Madsen MG, Vasquez JL, et al
    Validation of a Novel Assessment Tool Identifying Proficiency in Transurethral Bladder Tumor Resection: The OSATURBS Assessment Tool.
    J Endourol. 2022;36:572-579.
    PubMed         Abstract available

  58. SARI MOTLAGH R, Rajwa P, Mori K, Laukhtina E, et al
    Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy So
    J Endourol. 2022;36:535-547.
    PubMed         Abstract available

    J Histochem Cytochem

  59. HARDY CSC, Ghaedi H, Slotman A, Sjodahl G, et al
    Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
    J Histochem Cytochem. 2022 Apr 19:221554221095530.
    PubMed         Abstract available

    J Immunol Res

  60. ZHAO H, Chen Z, Fang Y, Su M, et al
    Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    J Immunol Res. 2022;2022:1793005.
    PubMed         Abstract available

    JAMA Netw Open

  61. LEWICKI P, Basourakos SP, Arenas-Gallo C, Qiu Y, et al
    Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial.
    JAMA Netw Open. 2022;5:e220602.

    Mol Carcinog

  62. CHEN X, Ou Z, Wang L, Zhang Z, et al
    Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
    Mol Carcinog. 2022;61:311-321.
    PubMed         Abstract available

    Mol Cell Biochem

  63. DIETRICH F, Cappellari AR, Filippi-Chiela EC, de Paula PB, et al
    High P2X6 receptor expression in human bladder cancer predicts good survival prognosis.
    Mol Cell Biochem. 2022 Apr 16. pii: 10.1007/s11010-022-04425.
    PubMed         Abstract available

    Nat Commun

  64. SU Z, Monshaugen I, Wilson B, Wang F, et al
    TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer.
    Nat Commun. 2022;13:2165.
    PubMed         Abstract available

    Nihon Hinyokika Gakkai Zasshi

  65. MATSUMURA S, Yoshida T, Imanaka T, Yamanaka K, et al
    Nihon Hinyokika Gakkai Zasshi. 2021;112:58-64.
    PubMed         Abstract available

  66. MAEDA K, Mori Y, Nakamura M, Harada Y, et al
    Nihon Hinyokika Gakkai Zasshi. 2021;112:100-104.
    PubMed         Abstract available

  67. UEMURA T, Ishibashi T, Pae S, Shirakawa N, et al
    Nihon Hinyokika Gakkai Zasshi. 2021;112:89-95.
    PubMed         Abstract available

    Open Vet J

  68. NISHIMORI T, Hanazono K, Matsuda K, Kawamura Y, et al
    Prognostic role of DeltaNp63 expression in canine transitional cell carcinoma of the urinary bladder.
    Open Vet J. 2021;11:700-706.
    PubMed         Abstract available

  69. GOVONI VM, Pigoli C, Sueiro FAR, Zuliani F, et al
    Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma.
    Open Vet J. 2021;11:535-543.
    PubMed         Abstract available

    Optom Vis Sci

    Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
    Optom Vis Sci. 2022;99:88-92.
    PubMed         Abstract available

    Pathol Res Pract

  71. WANG SS, Zhai GQ, Chen G, Huang ZG, et al
    Decreased expression of transcription factor Homeobox A11 and its potential target genes in bladder cancer.
    Pathol Res Pract. 2022;233:153847.
    PubMed         Abstract available


  72. HUANG Z, Gao H, Qing L, Wang B, et al
    A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/betacatenin signaling pathway.
    PeerJ. 2022;10:e13220.
    PubMed         Abstract available

    PLoS One

  73. KANG DH, Cho KS, Moon YJ, Chung DY, et al
    Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.
    PLoS One. 2022;17:e0267410.
    PubMed         Abstract available

    Prog Urol

  74. ROLLIN P, Xylinas E, Lanz C, Audenet F, et al
    [Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
    Prog Urol. 2022;32:326-331.
    PubMed         Abstract available

    RSC Adv

  75. FISHER L
    Retraction: Exosome-derived PTENP1 suppresses cisplatin resistance of bladder cancer (BC) by suppressing cell proliferation, migration and inducing apoptosis via the miR-103a/PDCD4 axis.
    RSC Adv. 2021;11:6254.
    PubMed         Abstract available

    Semin Ophthalmol

  76. ALKAN S, Evlice O, Agin A
    The Evaluation of Cases with Ocular Complications due to Bacillus Calmette-Guerin (BCG) Treatment using the Pool Analysis Method.
    Semin Ophthalmol. 2022;37:373-378.
    PubMed         Abstract available

    Support Care Cancer

  77. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer.
    Support Care Cancer. 2022 Apr 14. pii: 10.1007/s00520-022-07043.
    PubMed         Abstract available

  78. JUNG A, Crandell JL, Nielsen ME, Smith SK, et al
    Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle-invasive bladder cancer survivors.
    Support Care Cancer. 2022 Apr 18. pii: 10.1007/s00520-022-07034.
    PubMed         Abstract available

    Ther Adv Urol

  79. D'ELIA C, Trenti E, Krause P, Pycha A, et al
    Xpert(R) bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results.
    Ther Adv Urol. 2022;14:17562872221090320.
    PubMed         Abstract available

    Urol Oncol

  80. DANESHMAND S, Brummelhuis ISG, Pohar KS, Steinberg GD, et al
    The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00059.
    PubMed         Abstract available

  81. SORCE G, Chierigo F, Flammia RS, Hoeh B, et al
    Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00105.
    PubMed         Abstract available

  82. LI Z, Zhang Z, Ma H, Yao K, et al
    Extraperitonealization of ileal conduit reduces parastomal hernia after cystectomy and ileal conduit diversion.
    Urol Oncol. 2022;40:162.
    PubMed         Abstract available

  83. MUZAAIL HH, El-Assmy A, Harraz AM, Awadalla A, et al
    Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909.
    Urol Oncol. 2022 Apr 13. pii: S1078-1439(22)00078.
    PubMed         Abstract available

  84. GONZALEZ-PADILLA DA, Subiela JD, Gonzalez-Diaz A, Hernandez-Arroyo M, et al
    Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center.
    Urol Oncol. 2022 Apr 14. pii: S1078-1439(22)00067.
    PubMed         Abstract available

  85. PIERCONTI F, Martini M, Cenci T, Fiorentino V, et al
    The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
    Urol Oncol. 2022;40:108.
    PubMed         Abstract available

  86. WOO S, Ghafoor S, Das JP, Gangai N, et al
    Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival.
    Urol Oncol. 2022;40:108.
    PubMed         Abstract available

  87. YANG CH, Weng WC, Ou YC, Lin YS, et al
    Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of upper tract urothelial carcinoma: A retrospective cohort study from bench to bedside.
    Urol Oncol. 2022;40:109.
    PubMed         Abstract available

  88. LYON TD, Faraj KS, Brennan E, Tyson MD 2nd, et al
    Defining radical cystectomy using the ICD-10 procedure coding system.
    Urol Oncol. 2022;40:165.
    PubMed         Abstract available

  89. FLAMMIA RS, Chierigo F, Wurnschimmel C, Horlemann B, et al
    Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.
    Urol Oncol. 2022;40:165.
    PubMed         Abstract available

  90. PARK CK, Cho NH
    Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Urol Oncol. 2022;40:109.
    PubMed         Abstract available

  91. VENKAT S, Khan AI, Lewicki PJ, Borregales L, et al
    Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.
    Urol Oncol. 2022;40:108.
    PubMed         Abstract available

  92. AYDIN AM, Reich RR, Cao B, Cheriyan SK, et al
    Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy.
    Urol Oncol. 2022;40:164.
    PubMed         Abstract available

  93. YU A, Wang Y, Mossanen M, Preston M, et al
    Robotic-assisted radical cystectomy is associated with lower perioperative mortality in octogenarians.
    Urol Oncol. 2022;40:163.
    PubMed         Abstract available

  94. ALBISINNI S, Diamand R, Mjaess G, Assenmacher G, et al
    Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion does not increase hemorrhagic complications: results from a large multicentric cohort.
    Urol Oncol. 2022;40:163.
    PubMed         Abstract available

  95. RANTI D, Pfail J, Garcia M, Razdan S, et al
    Neobladder creation in patients with chronic kidney disease: A viable diversion strategy.
    Urol Oncol. 2022;40:168.
    PubMed         Abstract available

  96. TAOKA R, Kobayashi T, Hidaka Y, Abe H, et al
    Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:107.
    PubMed         Abstract available

  97. SHIGETA K, Matsumoto K, Ogihara K, Murakami T, et al
    Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Urol Oncol. 2022;40:105.
    PubMed         Abstract available

  98. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder.
    Urol Oncol. 2022;40:107.
    PubMed         Abstract available

  99. MITCHELL KA, Williams H
    Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes.
    Urol Oncol. 2022;40:126-132.
    PubMed         Abstract available

    World J Urol

  100. GUO B, Liu M
    The role of chemotherapy in patients with pure squamous cell bladder carcinoma.
    World J Urol. 2022;40:865-866.

    Zhonghua Zhong Liu Za Zhi

  101. XU H, Shi HL, Hao JW, Shu KP, et al
    [Casticin inhibits the proliferation, migration and invasion of bladder cancer cells by inhibition of TM7SF4 expression].
    Zhonghua Zhong Liu Za Zhi. 2022;44:334-340.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.